Clinical trials of Hirulog in patients undergoing high-risk percutaneous transluminal coronary angioplasty

Coronary Artery Disease

Volumn 7, Issue 6, 1996, Pages 449-454

  Bittl, John A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

activated clotting time; acute myocardial infarction; angina pectoris; percutaneous transluminal coronary angioplasty; restenosis; thrombin; thrombus; unstable angina

Indexed keywords

HIRULOG; THROMBIN;

ACUTE HEART INFARCTION; BLOOD CLOTTING TIME; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBUS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0029782578     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199606000-00007     Document Type: Review

References (64)

1. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW: Design and characterization of Hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990, 29:7095-7101.
2. Fuster V, Badimon JJ, Badimon L: Clinical-pathological correlations of coronary disease progression and regression. Circulation 1992, 86 (suppl III)III1-III11.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathophysiology of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242-250, 310-318. This paper reviews the experimental and clinical evidence for endothelial dysfunction, plaque rupture, and thrombus formation in the genesis of unstable coronary syndromes.
4. Annex BH, Denning SM, Channon KM, et al.: Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995, 91:619-622
5. Coughlin SR, Vu THH, Hung DR, Wheaton VI: Characterization of a functional thrombin receptor. J Clin Invest 1992, 89:351-355.
6. Coller BS, Peerschke EI, Scudder LE, Sullivan CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and / or IIIa. J Clin Invest 1983, 72:325-338.
7. Young E, Prins M, Levine MN, Hirsh J: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992, 67:639-643.
8. Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL: Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976, 53:691-695.
9. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, March KC, Leachman DR: Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994, 23:1061-1065.
10. Eitzmann DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP: Heparin neutralization by platelet-rich thrombi: role of platelet factor 4. Circulation 1994, 89:1523-1529.
11. Ambrose JA, Winters SL, Stern A, et al.: Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985; 5:609-614. This report is the seminal angiographic study of unstable angina, showing that patients with unstable ischemic syndromes are more likely than those with stable clinical presentations to have culprit lesions associated with complex angiographic features.
12. Ahmed WH, Bittl JA, Braunwald E: Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am J Cardiol 1993, 72:544-550.
13. Gotoh K, Minamino T, Katoh O, et al.: The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation 1988, 77:526-534.
14. Sherman CT, Litvack F, Grundfest W, et al.: Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986, 315:913-919.
15. Mizuno K, Satomura K, Miyamoto A, et al.: Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992, 326:287-291. This study demonstrated that patients with unstable angina had a high incidence of coronary lesions associated with white platelet-rich thrombus, and patients with acute myocardial infarction had a high incidence of lesions associated with erythrocyte and fibrin-rich thrombi. These findings have implications for treatment strategies for patients with acute ischemic syndromes.
16. Forrester JS, Litvack F, Grundfest W, Mickey A: A perspective of coronary disease seen through the arteries of living man. Circulation 1986, 75:505-512.
17. Falk E: Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 1983, 71:699-708.
18. Davies MJ, Thomas AC: Plaque-fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985, 53:363-373.
19. Davies MJ, Thomas AC, Knapman PA, Hangartner JR: Intramyocardial platelet aggregation in patients with unstable angina suffering ischemic cardiac death. Circulation 1986, 73:418-427.
20. Lendon CL, Davies MJ, Born GV, Richardson PD: Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 1991, 87:87-90.
21. Flugelman MY, Virmani R, Correa R, et al.: Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. Circulation 1993, 88:2493-2500. Only 34% of patients with the clinical diagnosis of unstable angina had histologic evidence of a thrombus in lesions subjected to directional atherectomy. This suggests that the majority of patients with unstable angina have other mechanisms such as plaque inflammation responsible for the precipitation of their acute ischemic syndromes.
22. Hogg PJ, Jackson CM: Fibrin monomer protects thrombin from inactivation by heparin antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989, 86:3619-3623.
23. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391. This careful analysis revealed that heparin in concentrations conventionally thought to be therapeutic (0.2-0.4 u/ml) has only 20% of the thrombin-neutralizing activity against clot-bound thrombin which it has against soluble thrombin. The direct thrombin inhibitor, hirugen, has equivalent inhibitory effects against clot-bound and soluble thrombin.
24. Hillegass WB, Narins CR, Brott BC, et al.: Activated clotting time predicts bleeding complications from angioplasty [abstract]. J Am Coll Cardiol 1994, 23:184A.
25. Cannon CP, McCabe CH, Henry TD, et al.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Mycardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994, 23:993-1003.
26. Hamelink JK, Tang DB, Barr CF, et al.: Inhibition of platelet deposition by combined Hirulog and aspirin in a rat carotid endarterectomy model. Surgery 1995, 21:492-498.
27. de Feyter PJ, Serruys PW: Percutaneous transluminal coronary angioplasty for unstable angina. In Textbook of Interventional Cardiology. Edited by Topol EJ. Philadelphia: W.B. Saunders, Co.; 1994:274-291.
28. de Feyter PJ, Serruys PW, Soward A, van der Brand M, Bos E, Hugenholtz PG: Coronary angioplasty for early postinfarction unstable angina. Circulation 1986, 74:1365-1370.
29. Holt GW, Sugrue DD, Bresnahan JF, et al.: Results of percutaneous transluminal coronary angioplasty for unstable angina pectoris in patients 70 years of age and older. Am J Cardiol 1988, 61:994-997.
30. Gottlieb SO, Walford GD, Ouyang P, et al.: Initial and late results of coronary angioplasty for early postinfarction unstable angina. Cath Cardiovasc Diagn 1987, 13:93-99.
31. Safian RD, Snyder LD, Snyder BA, et al.: Usefulness of percutaneous transluminal coronary angioplasty for unstable angina pectoris after non-Q-wave acute myocardial infarction. Am J Cardiol 1987, 59:263-266.
32. Hopkins J, Savage M, Zalewski A, Dervan JP, Goldberg S: Recurrent ischemia in the zone of prior myocardial infarction: result of coronary angioplasty of the infarct-related artery. Am Heart J 1988, 115:14-19.
33. Suryapranata H, Beatt K, de Feyter PJ, et al.: Percutaneous transluminal coronary angioplasty for angina pectoris after a non-Q-wave acute myocardial infarction. Am J Cardiol 1988, 61:240-243.
34. Morrison DA: Coronary angioplasty for medically refractory unstable angina in patients with prior coronary bypass surgery. Cath Cardiovasc Diagn 1990, 20:174-181.
35. TIMI Study Group Phase II Trial: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1989, 320:618-627.
36. Timmis AD, Griffin B, Crick JC, Sowton E: Early percutaneous transluminal coronary angioplasty in the management of unstable angina. Int J Cardiol 1987, 14:25-31.
37. de Feyter PJ, Suryapranata H, Serruys PW, et al.: Coronary angioplasty for unstable angina: immediate and late results in 200 consecutive patients with identification of risk factors for unfavorable early and late outcome. J Am Coll Cardiol 1988, 12:324-333.
38. Thijs Plokker HW, Ernst SM, Bal ET, et al.: Percutaneous transluminal coronary angioplasty in patients with unstable angina pectoris refractory to medical therapy: long-term clinical and angiographic results. Cath Cardiovasc Diagn 1988, 14:15-18.
39. Sharma B, Wyeth RP, Kilath GS, Gimenez HJ, Franciosa JA: Percutaneous transluminal coronary angioplasty of one vessel for refractory unstable angina pectoris: efficacy in single and multivessel disease. Br Heart J 1988, 59:280-286.
40. Perry RA, Seth A, Hunt A, Shiu MF: Coronary angioplasty in unstable angina and stable angina: a comparison of success and complications. Br Heart J 1988, 60:367-372.
41. Myler RK, Shaw RE, Stertzer SH, et al.: Unstable angina and coronary angioplasty [review]. Circulation 1990, 82:II88-II95.
42. Morrison DA: Percutaneous transluminal coronary angioplasty for rest angina pectoris requiring intravenous nitroglycerin and intra-aortic balloon counterpulsation. Am J Cardiol 1990, 66:168-172.
43. Rupprecht HJ, Brennecke R, Kottmeyer M, et al.: Short-and long-term outcome after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina. Eur Heart J 1990, 11:964-969.
44. Quigley PJ, Erwin J, Maurer BJ, Walsh MJ, Gearty GF: Percutaneous transluminal coronary angioplasty in unstable angina. Br Heart J 1986, 55:227-230.
45. Steffenino G, Meier B, Finci L, Rutishauser W: Follow up results of treatment of unstable angina by coronary angioplasty. Br Heart J 1987, 57:416-419.
46. Stammen F, de Scheerder I, Glazier JJ, et al.: Immediate and follow-up results of the conservative coronary angioplasty strategy for unstable angina pectoris. Am J Cardiol 1992, 69:1533-1537.
47. Bredlau CE, Roubin GS, Leimgruber PP, Douglas JS Jr, King S III, Gruentzig AR: In-hospital morbidity and mortality in patients undergoing elective coronary angioplasty. Circulation 1985, 72:1044-1052.
48. Hartzler G. Complex coronary angioplasty: multivessel/multilesion dilatation. Practice of Coronary Angioplasty. Edited by Ischinger T. New York: Springer-Verlag; 1986:250-267.
49. Holmes DR Jr, Holubkov R, Vlietstra RE, et al.: Comparison of complications during percutaneous transluminal angioplasty from 1977 to 1981 and from 1985 to 1986: The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988, 12:1149-1155.
50. Tuzcu EM, Simpfendorfer C, Badhwar K, et al.: Determinants of primary success in elective percutaneous transluminal coronary angioplasty for signficant narrowing of a single major coronary artery. Am J Cardiol 1988, 62:873-875.
51. de Feyter PJ, van den Brand M, Serruys PW: Increase of initial success and safety of single-vessel PTCA in 1371 patients: a seven-years' experience. J Intervent Cardiol 1988, 1:1-10.
52. O'Keefe JH Jr, Reeder GS, Miller GA, Bailey KR, Holmes DR Jr: Safety and efficacy of percutaneous transluminal coronary angioplasty performed at time of diagnostic catheterization compared with that performed at other times. Am J Cardiol 1989, 63:27-29.
53. Myler RK, Shaw RE, Stertzer SH, et al.: Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol 1992, 19:1641-1652.
54. Dimas AP, Grigera F, Arora RR, et al.: Repeat coronary angioplasty as treatment for restenosis. J Am Coll Cardiol 1992, 19:1310-1314.
55. Weintraub WS, Ghazzal ZMB, Douglas JS, et al.: Initial management and long-term clinical outcome of restenosis after initially successful percutaneous transluminal coronary angioplasty. Am J Cardiol 1992, 70:47-55.
56. Alfonso R, Macaya C, Iniquez A, Zarco P: Repeat coronary angioplasty during the same angiographic diagnosis of coronary restenosis. Am Heart J 1990, 119:237-241.
57. Meier B, King SB III, Gruentzig AR, et al.: Repeat coronary angioplasty. J Am Coll Cardiol 1984, 4:463-466.
58. Topol EJ, Bonan R, Jewitt D, et al.: Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622-1629. This study reports the safety results of Hirulog instead of heparin during coronary angioplasty. This is the first demonstration of coronary angioplasty performed in patients without heparin.
59. Bittl JA, Stony J, Brinker JA: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Engl J Med 1996, 333:764-769. In this phase III trial of patients undergoing angioplasty for unstable or post-infarction angina, Hirulog therapy resulted in slightly lower rates of major ischemic complications and strikingly lower rates of major hemorrhage.
60. Grassman ED, Leya F, Johnson SA, et al.: Percutaneous transluminal coronary angioplasty for unstable angina: predictors of outcome in a multicenter study. J Thromb Thrombolys 1994, 1:73-78.
61. Wolfe MW, Roubin GS, Schweiger M, et al.: Length of hospital stay and complications after percutaneous transluminal coronary angioplasty: clinical and procedural predictors. Circulation 1995, 92:311-319
62. Marmur JD, Merlinie PA, Sharma SK, et al.: Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994, 24:1484-1491.
63. Bittl JA, on behalf of the Hirulog Angioplasty Study Investigators: Comparative safety profiles of Hirulog and heparin in patients undergoing angioplasty. Am Heart J 1995, 130:658-665.
64. Chesebro JH, Webster MWI, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ: Antithrombotic therapy and progression of coronary artery disease: Antiplatelet versus antithrombins. Circulation 1992, 86 (suppl III):III100-III111.